30 patients will participate in a prospective randomized clinical trial to test the safety, tolerability and efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) for autonomic nervous system (ANS) dysfunction in the chronic kidney disease (CKD) stage 3-5 setting.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Proportion of Patients who Complete 2 Weeks of Intervention
Timeframe: Week 2
Proportion of Patients who Tolerate Each Full 15-Minute Session
Timeframe: Week 2
Incidence of Severe Bradycardia following taVNS Use
Timeframe: Up to Week 2
Incidence of Severe Tachycardia following taVNS Use
Timeframe: Up to Week 2
Incidence of Syncope following taVNS Use
Timeframe: Up to Week 2